Skip to main content
. 2022 Nov 17;13:1043217. doi: 10.3389/fphar.2022.1043217

TABLE 4.

Treatment-related AEs (TRAEs).

Adverse event Chemotherapy TKIs + chemotherapy TKIs + ICIs
All grade ≥ Grade3 All grade ≥ Grade3 All grade ≥ Grade3
Hematologic
 Decreased white blood count 38 (62.3) 6 (9.8) 29 (61.7) 5 (10.6) 3 (5.6) 0
 Decreased neutrophil count 38 (62.3) 5 (8.2) 29 (61.7) 5 (10.6) 3 (5.6) 0
 Anemia 18 (29.5) 2 (3.3) 16 (34.0) 1 (2.1) 8 (14.8) 0
 Decreased platelet 8 (13.1) 0 6 (12.8) 0 6 (11.1) 0
 Increased ALT/AST 10 (16.4) 1 (1.6) 9 (19.1) 1 (2.1) 5 (9.3) 0
 Hypercholesterolemia 4 (6.6) 0 4 (8.5) 0 5 (9.3) 0
 Hypertriglyceridemia 4 (6.6) 0 3 (6.4) 0 8 (14.8) 0
 LDL elevation 2 (3.3) 0 3 (6.4) 0 6 (11.1) 0
 TSH elevation 0 0 0 () 0 11 (20.4) 0
Non-hematologic
 Fatigue 16 (26.2) 0 17 (36.2) 0 20 (37.0) 0
 Nausea or Vomiting 20 (32.8) 2 (3.3) 14 (29.8) 1 (2.1) 2 (3.7) 0
 Diarrhea 11 (18.0) 1 (1.6) 8 (17.0) 0 2 (3.7) 0
 Muscle pain/joint pain 18 (29.5) 0 8 (17.0) 1 (2.1) 0 0
 Sensory neurotoxicity 20 (32.8) 2 (3.3) 10 (21.3) 0 0 0
 Secondary hypertension 0 0 13 (27.7) 1 (2.1) 20 (37.0) 5 (9.3)
 Hand-foot syndrome 0 0 12 (25.5) 3 (6.4) 16 (29.6) 3 (5.6)
 Proteinuria 0 0 10 (21.3) 0 13 (24.1) 0
 Rash 2 (3.3) 0 6 (12.8) 0 14 (25.9) 1 (1.9)
 Pneumonitis 0 0 0 () 0 5 (9.3) 1 (1.9)
 Oral mucositis 4 (6.6) 0 3 (6.4) 0 6 (11.1) 0
 Hypothyroidism 0 0 0 () 0 11 (20.4) 0
 Gum bleeding 0 0 4 (8.5) 0 3 (5.6) 0

AE, adverse event.